Brokerages Set TScan Therapeutics, Inc. (NASDAQ:TCRX) Target Price at $6.00

TScan Therapeutics, Inc. (NASDAQ:TCRX) has earned a consensus rating of “Hold” from the six research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $6.00.

A number of research analysts recently weighed in on the stock. Wedbush raised their target price on shares of TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a research report on Thursday, March 5th. Wall Street Zen cut shares of TScan Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Thursday, January 22nd.

Insider Transactions at TScan Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp purchased 75,500 shares of TScan Therapeutics stock in a transaction that occurred on Monday, December 22nd. The stock was purchased at an average cost of $0.90 per share, with a total value of $67,950.00. Following the completion of the transaction, the insider owned 8,012,916 shares of the company’s stock, valued at approximately $7,211,624.40. This trade represents a 0.95% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On TScan Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in shares of TScan Therapeutics in the 2nd quarter valued at approximately $309,000. Vanguard Group Inc. increased its holdings in TScan Therapeutics by 7.8% during the third quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company’s stock worth $4,219,000 after buying an additional 168,540 shares during the last quarter. Renaissance Technologies LLC raised its position in TScan Therapeutics by 37.5% during the fourth quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock worth $1,141,000 after acquiring an additional 311,150 shares in the last quarter. Marshall Wace LLP raised its position in TScan Therapeutics by 627.5% during the fourth quarter. Marshall Wace LLP now owns 339,240 shares of the company’s stock worth $339,000 after acquiring an additional 292,610 shares in the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in TScan Therapeutics by 35.7% in the second quarter. Bridgeway Capital Management LLC now owns 153,700 shares of the company’s stock valued at $223,000 after acquiring an additional 40,400 shares during the last quarter. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Stock Performance

NASDAQ TCRX opened at $1.04 on Monday. TScan Therapeutics has a 52 week low of $0.88 and a 52 week high of $2.57. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.41 and a current ratio of 8.41. The stock’s 50 day moving average price is $1.07 and its two-hundred day moving average price is $1.34. The stock has a market capitalization of $59.18 million, a price-to-earnings ratio of -1.04 and a beta of 1.03.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.09. The company had revenue of $2.57 million during the quarter, compared to analysts’ expectations of $2.44 million. TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on equity of 79.36%. As a group, analysts anticipate that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.